At the annual congress of the European Society of Medical Oncology (ESMO 2021), Japan’s Astellas Pharma (TSE: 4503) and partner Pfizer (NYSE: PFE) are offering new data for Xtandi (enzalutamide).
Data from the Phase III ARCHES study show the androgen receptor blocker improved overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC), compared with placebo.
In the test group, the risk of death was reduced by 34% at the time of the analysis, while median OS was not reached in either treatment group.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze